We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …

PURPOSE Venous thromboembolism (VTE) is a leading cause of death among patients with
cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with …

Cancer-associated thrombosis is a leading cause of non-cancer death in cancer patients
and is comprised of both arterial and venous thromboembolism (VTE). There are multiple …

BACKGROUND. Protein disulfide isomerase (PDI) is a thiol isomerase secreted by vascular
cells that is required for thrombus formation. Quercetin flavonoids inhibit PDI activity and …

PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and
lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable …

Venous and arterial thromboembolism are prevalent, highly burdensome, and associated
with risk of worse outcomes for patients with cancer. Risk for venous thromboembolism …